Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure

Research output: Contribution to journalJournal articlepeer-review

Standard

Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure. / Schwab, Martin; McGoverin, Cushla M; Gordon, Keith C; Winter, Gerhard; Rades, Thomas; Myschik, Julia; Strachan, Clare J.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 84, No. 3, 08.2013, p. 456-63.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Schwab, M, McGoverin, CM, Gordon, KC, Winter, G, Rades, T, Myschik, J & Strachan, CJ 2013, 'Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure', European Journal of Pharmaceutics and Biopharmaceutics, vol. 84, no. 3, pp. 456-63. https://doi.org/10.1016/j.ejpb.2012.12.023

APA

Schwab, M., McGoverin, C. M., Gordon, K. C., Winter, G., Rades, T., Myschik, J., & Strachan, C. J. (2013). Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure. European Journal of Pharmaceutics and Biopharmaceutics, 84(3), 456-63. https://doi.org/10.1016/j.ejpb.2012.12.023

Vancouver

Schwab M, McGoverin CM, Gordon KC, Winter G, Rades T, Myschik J et al. Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure. European Journal of Pharmaceutics and Biopharmaceutics. 2013 Aug;84(3):456-63. https://doi.org/10.1016/j.ejpb.2012.12.023

Author

Schwab, Martin ; McGoverin, Cushla M ; Gordon, Keith C ; Winter, Gerhard ; Rades, Thomas ; Myschik, Julia ; Strachan, Clare J. / Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure. In: European Journal of Pharmaceutics and Biopharmaceutics. 2013 ; Vol. 84, No. 3. pp. 456-63.

Bibtex

@article{8d3f19d3410a468c97b24a51757ebdd7,
title = "Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure",
abstract = "It has recently been found that lipid composition appears to have a major influence on the rate of lipase-induced degradation of lipid-based extended release drug delivery systems (microparticles, compressed implants and extrudated implants). Previously, we have found that during lipase incubation, depending on the lipid used, lipidic extrudates can lose their physical strength and collapse generating lipid particles in the μm-range. The aim of this study was to characterise the processes leading to collapse of solid lipid-based drug delivery systems during in vitro lipase incubation. Compressed lipid implants were used as model systems. Free fatty acids (FFA) generated in the incubation experiments were derivatised and subsequently analysed via reversed phase-HPLC in order to characterise the degradation behaviour of single lipid components (glyceryltrilaurate (D112), glyceryltrimyristate (D114), glyceryltripalmitate (D116) and glyceryltristearate (D118)) used for the preparation of compressed lipid implants. Further, Raman spectroscopy/microscopy, differential scanning calorimetry, scanning electron and light microscopy were used to investigate the physical and chemical changes in the implants upon lipase incubation. This study revealed that the lipid component D112 plays a major role in the degradation and erosion processes occurring during lipase incubation of lipid implants. The production of D112/lauric acid mixtures, with a melting point below human body temperature, leads to lipid matrices melting and losing their physical integrity.",
author = "Martin Schwab and McGoverin, {Cushla M} and Gordon, {Keith C} and Gerhard Winter and Thomas Rades and Julia Myschik and Strachan, {Clare J}",
note = "Copyright {\textcopyright} 2013 Elsevier B.V. All rights reserved.",
year = "2013",
month = aug,
doi = "10.1016/j.ejpb.2012.12.023",
language = "English",
volume = "84",
pages = "456--63",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure

AU - Schwab, Martin

AU - McGoverin, Cushla M

AU - Gordon, Keith C

AU - Winter, Gerhard

AU - Rades, Thomas

AU - Myschik, Julia

AU - Strachan, Clare J

N1 - Copyright © 2013 Elsevier B.V. All rights reserved.

PY - 2013/8

Y1 - 2013/8

N2 - It has recently been found that lipid composition appears to have a major influence on the rate of lipase-induced degradation of lipid-based extended release drug delivery systems (microparticles, compressed implants and extrudated implants). Previously, we have found that during lipase incubation, depending on the lipid used, lipidic extrudates can lose their physical strength and collapse generating lipid particles in the μm-range. The aim of this study was to characterise the processes leading to collapse of solid lipid-based drug delivery systems during in vitro lipase incubation. Compressed lipid implants were used as model systems. Free fatty acids (FFA) generated in the incubation experiments were derivatised and subsequently analysed via reversed phase-HPLC in order to characterise the degradation behaviour of single lipid components (glyceryltrilaurate (D112), glyceryltrimyristate (D114), glyceryltripalmitate (D116) and glyceryltristearate (D118)) used for the preparation of compressed lipid implants. Further, Raman spectroscopy/microscopy, differential scanning calorimetry, scanning electron and light microscopy were used to investigate the physical and chemical changes in the implants upon lipase incubation. This study revealed that the lipid component D112 plays a major role in the degradation and erosion processes occurring during lipase incubation of lipid implants. The production of D112/lauric acid mixtures, with a melting point below human body temperature, leads to lipid matrices melting and losing their physical integrity.

AB - It has recently been found that lipid composition appears to have a major influence on the rate of lipase-induced degradation of lipid-based extended release drug delivery systems (microparticles, compressed implants and extrudated implants). Previously, we have found that during lipase incubation, depending on the lipid used, lipidic extrudates can lose their physical strength and collapse generating lipid particles in the μm-range. The aim of this study was to characterise the processes leading to collapse of solid lipid-based drug delivery systems during in vitro lipase incubation. Compressed lipid implants were used as model systems. Free fatty acids (FFA) generated in the incubation experiments were derivatised and subsequently analysed via reversed phase-HPLC in order to characterise the degradation behaviour of single lipid components (glyceryltrilaurate (D112), glyceryltrimyristate (D114), glyceryltripalmitate (D116) and glyceryltristearate (D118)) used for the preparation of compressed lipid implants. Further, Raman spectroscopy/microscopy, differential scanning calorimetry, scanning electron and light microscopy were used to investigate the physical and chemical changes in the implants upon lipase incubation. This study revealed that the lipid component D112 plays a major role in the degradation and erosion processes occurring during lipase incubation of lipid implants. The production of D112/lauric acid mixtures, with a melting point below human body temperature, leads to lipid matrices melting and losing their physical integrity.

U2 - 10.1016/j.ejpb.2012.12.023

DO - 10.1016/j.ejpb.2012.12.023

M3 - Journal article

C2 - 23385286

VL - 84

SP - 456

EP - 463

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 3

ER -

ID: 46406259